Crossmark

The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition

Published Online: 2016-10-13

Authors

Wu, Shang-Gin

Chang, Yih-Leong

Yu, Chong-Jen

Yang, Pan-Chyr

Shih, Jin-Yuan
License Information

Text and Data Mining valid from 2016-10-13

Version of Record valid from 2016-10-13
More Information

Article History

Received: 19 July 2016

Accepted: 27 September 2016

First Online: 13 October 2016

Competing interests

: Jin-Yuan Shih received speaking honoraria from AstraZeneca, Roche, Pfizer, Boehringer Ingelheim, Merck Sharp & Dohme (MSD), Novartis and Eli Lilly. All other authors report no conflicts of interest.

Document is current